Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01016600 · ClinicalTrials.gov registry record · Phase 1
Azacitidine and Lenalidomide for Acute Myeloid Leukemia
A Phase 1 study of Leukemia, Myeloid, Acute, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT01016600: Completed Phase 1 study of Leukemia, Myeloid, Acute, sponsored by Washington University School of Medicine.
NCT01016600 is a Phase 1 study of Leukemia, Myeloid, Acute that has completed, run by Washington University School of Medicine. The registered enrollment target is 31 participants, below the 115-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01016600, a Phase 1 study of Leukemia, Myeloid, Acute, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
Determine toxicity and remission rates of treatment with azacitidine and lenalidomide for patients with Acute Myeloid Leukemia
Primary Outcome
* The maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity during the first cycle. * Hematologic DLT is as a persistent bone marrow aplasia with ≤ 10 % cellularity, which persists for \> 60 days from the start of a chemotherapy cycle. * Non-hematologic DLT is defined as any Grade 3 or Grade 4 non-hematologic toxicity that occurs during the first cycle with the specific exc
Conditions Studied
Interventions
- DRUG Azacitidine
- DRUG Lenalidomide
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
What the finished NCT01016600 record still lists
NCT01016600 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 115-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Leukemia, Myeloid, Acute appearing as the primary indexed condition, and to 2 interventions - of which Azacitidine is the first listed.
NCT01016600 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT01016600 about?
NCT01016600 is a clinical study titled "Azacitidine and Lenalidomide for Acute Myeloid Leukemia". Determine toxicity and remission rates of treatment with azacitidine and lenalidomide for patients with Acute Myeloid Leukemia
What is the current status of trial NCT01016600?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2010-04. Estimated completion is 2014-10.
What conditions does trial NCT01016600 study?
This clinical trial studies the following conditions: Leukemia, Myeloid, Acute.
What interventions are being tested in trial NCT01016600?
The interventions under investigation include: Azacitidine (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01016600?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01016600 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Myeloid, Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01016600's enrollment target sits among peer trials
31 23rd of 30 higher than 8 of 30 other Leukemia, Myeloid, Acute trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia, Myeloid, Acute trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
RECRUITING · Phase 1
-
CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
RECRUITING · Phase 1
-
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia